PL3082878T3 - Łączniki karbaminianu metylenu do zastosowania z ukierunkowanymi koniugatami leku - Google Patents
Łączniki karbaminianu metylenu do zastosowania z ukierunkowanymi koniugatami lekuInfo
- Publication number
- PL3082878T3 PL3082878T3 PL14871434.8T PL14871434T PL3082878T3 PL 3082878 T3 PL3082878 T3 PL 3082878T3 PL 14871434 T PL14871434 T PL 14871434T PL 3082878 T3 PL3082878 T3 PL 3082878T3
- Authority
- PL
- Poland
- Prior art keywords
- targeted
- drug conjugates
- methylene carbamate
- carbamate linkers
- linkers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361918539P | 2013-12-19 | 2013-12-19 | |
PCT/US2014/071593 WO2015095755A1 (en) | 2013-12-19 | 2014-12-19 | Methylene carbamate linkers for use with targeted-drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3082878T3 true PL3082878T3 (pl) | 2023-01-23 |
Family
ID=72068148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL14871434.8T PL3082878T3 (pl) | 2013-12-19 | 2014-12-19 | Łączniki karbaminianu metylenu do zastosowania z ukierunkowanymi koniugatami leku |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP3082878B1 (pl) |
CN (2) | CN111558049A (pl) |
DK (1) | DK3082878T3 (pl) |
ES (1) | ES2931927T3 (pl) |
FI (1) | FI3082878T3 (pl) |
HU (1) | HUE060643T2 (pl) |
PL (1) | PL3082878T3 (pl) |
PT (1) | PT3082878T (pl) |
SI (1) | SI3082878T1 (pl) |
TW (2) | TWI777502B (pl) |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1357771A (en) * | 1971-05-07 | 1974-06-26 | Ici Ltd | Carbamoyloxime compounds and compositions and processes for pre paring them |
US3927070A (en) * | 1972-05-08 | 1975-12-16 | Karoly Szabo | M-(3,3-disubstituted ureido) phenyl {8 (substituted)methyl{9 {0 carbamates |
GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1997009066A1 (fr) * | 1995-09-08 | 1997-03-13 | Kanebo, Ltd. | INHIBITEUR DE SOLUBILISATION DE LIGAND Fas |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
CN1805951A (zh) * | 2003-06-12 | 2006-07-19 | 诺沃挪第克公司 | 取代的哌啶氨基甲酸酯用作激素敏感性脂酶抑制剂 |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
US7375078B2 (en) * | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
WO2005112919A2 (en) | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
DK1871418T3 (da) | 2005-04-19 | 2014-06-10 | Seattle Genetics Inc | Humaniserede anti-cd70-bindende midler og anvendelser deraf |
US8343928B2 (en) | 2005-07-07 | 2013-01-01 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
JP2009504783A (ja) * | 2005-08-19 | 2009-02-05 | エンドサイト,インコーポレイテッド | ビンカアルカロイド、類似体および誘導体のリガンド結合体 |
WO2008025020A2 (en) | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
US20110152252A1 (en) * | 2007-12-18 | 2011-06-23 | Institut Curie | Shiga toxin b-subunit/chemotherapeutics conjugates |
ES2647927T3 (es) | 2008-03-18 | 2017-12-27 | Seattle Genetics, Inc. | Conjugados enlazadores del fármaco auriestatina |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
US20130028917A1 (en) | 2010-04-15 | 2013-01-31 | Spirogen Developments Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2011140393A1 (en) * | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled release from macromolecular conjugates |
PT2917195T (pt) * | 2012-11-05 | 2018-02-09 | Pfizer | Análogos de spliceostatina |
EP3265474A1 (en) * | 2015-03-05 | 2018-01-10 | Sirenas LLC | Cyclic peptide analogs and conjugates thereof |
-
2014
- 2014-12-19 PL PL14871434.8T patent/PL3082878T3/pl unknown
- 2014-12-19 EP EP14871434.8A patent/EP3082878B1/en active Active
- 2014-12-19 FI FIEP14871434.8T patent/FI3082878T3/fi active
- 2014-12-19 DK DK14871434.8T patent/DK3082878T3/da active
- 2014-12-19 CN CN202010418302.6A patent/CN111558049A/zh active Pending
- 2014-12-19 EP EP22199573.1A patent/EP4212181A3/en active Pending
- 2014-12-19 TW TW110113994A patent/TWI777502B/zh active
- 2014-12-19 SI SI201432003T patent/SI3082878T1/sl unknown
- 2014-12-19 ES ES14871434T patent/ES2931927T3/es active Active
- 2014-12-19 TW TW111130451A patent/TW202313119A/zh unknown
- 2014-12-19 HU HUE14871434A patent/HUE060643T2/hu unknown
- 2014-12-19 CN CN202010417903.5A patent/CN111569086A/zh active Pending
- 2014-12-19 PT PT148714348T patent/PT3082878T/pt unknown
Also Published As
Publication number | Publication date |
---|---|
EP3082878B1 (en) | 2022-10-05 |
EP3082878A4 (en) | 2017-08-30 |
TWI777502B (zh) | 2022-09-11 |
PT3082878T (pt) | 2022-11-30 |
TW202128229A (zh) | 2021-08-01 |
CN111569086A (zh) | 2020-08-25 |
EP4212181A3 (en) | 2023-11-15 |
SI3082878T1 (sl) | 2023-01-31 |
CN111558049A (zh) | 2020-08-21 |
HUE060643T2 (hu) | 2023-04-28 |
TW202313119A (zh) | 2023-04-01 |
DK3082878T3 (da) | 2022-12-12 |
FI3082878T3 (fi) | 2022-12-15 |
ES2931927T3 (es) | 2023-01-04 |
EP4212181A2 (en) | 2023-07-19 |
EP3082878A1 (en) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290330A (en) | Methylene carbamate binders for use with drug-targeting conjugates | |
HUS2300020I1 (hu) | Pirrolobenzodiazepin-antitest konjugátumok | |
IL244816A0 (en) | Protein-polymer-drug conjugates | |
IL241277A0 (en) | Antibody-drug conjugates | |
IL245009A0 (en) | Attach a drug from a protein and a polymer | |
EP2970511A4 (en) | INSULIN CONJUGATES incretin | |
SG11201605260VA (en) | Var2csa-drug conjugates | |
PL2906296T3 (pl) | Koniugaty pirolobenzodiazepina-przeciwciało | |
ZA201508487B (en) | Antibody drug conjugates | |
EP2968381A4 (en) | MEDICAMENT CONJUGATES-SUGAR BINDING SEQUENCE | |
EP2917244A4 (en) | ANTIBODY CONJUGATES OBTAINED FROM APROTININE | |
SG11201604191UA (en) | Anti-efna4 antibody-drug conjugates | |
EP2968599A4 (en) | LIGAND THERAPEUTIC ACID JUGATES AND LINKERS ON SILICON BASE | |
SG10201708812YA (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
PL3082878T3 (pl) | Łączniki karbaminianu metylenu do zastosowania z ukierunkowanymi koniugatami leku | |
GB201310472D0 (en) | Antibody-drug conjugates |